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Authors’ response
We sincerely appreciate the interest in our
recent article published in Gut1 and1 the
comments raised. The comments by
Heneghan et al raised some important ques-
tions concerning the emerging circulating
microRNA (miRNA) aspects of cancer diag-
nostics. These comments include: (1) the
choice of circulating medium; (2) the choice of
endogenous control; (3) premature for colo-
rectal cancer (CRC) screening; and (4)whether
elevated miRNAs in plasma reﬂect a general
cancer phenomenon, or a trueCRCoccurrence.
In response to comment 1, based on our
experience and commercial kit recommenda-
tion, total RNA <50 ng is recommended for
quantitative PCR (qPCR) of miRNA. A large
amount of RNA cannot improve qPCR
results and so is unnecessary. Although we
agree with the authors that total RNA
extracted from whole blood generates a
higher yield than that from plasma or serum
because a high percentage of RNA/miRNA is
derived from the cellular portion in whole
blood, one concern about using whole blood
for cancer diagnosis is whether the elevated
miRNAs identiﬁed are primarily derived from
the tumour itself or are simply a secondary
response of blood cells during tumouri-
genesis. If the elevated miRNAs are mainly
due to the response of blood cells, those
miRNAs may not reﬂect the patient’s cancer
phenomenon and so lower the testing accu-
racy. Heneghan et al recently showed that
miR-195 and let-7a are elevated in blood
from patients with breast cancer. However,
a previous study by the same group of authors
demonstrated that let-7a is suitable as an
endogenous control for qPCR inbreast cancer.2
So, this raises the issue that let-7a elevation
in blood is probably due to a secondary
phenomenon such as inﬂammation from
blood cells. Accordingly, usingwhole blood for
this diagnostic purpose is questionable.
In response to comment 2, ideally an
absolute quantitation approach with stan-
dard curve calibration is recommended to be
used for qPCR in the ﬁeld of diagnostics.
For relative quantitation, there is still no
consensus on the use of an internal normal-
isation control in plasma. Downregulation of
miR-16 has been reported in several cancers
including leukaemia, pituitary adenomas,
prostate carcinoma and lung cancer.3e5 In
our laboratory, we also found that miR-16 in
plasma was aberrantly expressed in patients
with breast cancer (unpublished data). Thus,
the use of miR-16 as an internal normal-
isation control in whole blood is still ques-
tionable. Furthermore, it was surprising
that the same group of authors previously
recommended let-7a as one reliable endoge-
nous control in breast cancer.2 Accordingly,
let-7a is not likely to be breast cancer speciﬁc
and so it raises the issue as to whether let-7a
should be used as an endogenous control or
diagnostic marker for breast cancer. Thus, an
internal normalisation control is still a crit-
ical issue for debate. From our point of view,
we should eventually switch to an absolute
quantitation approach to eliminate the use
of an endogenous control.
With regard to comment 3, we agree with
the authors that it is premature to apply
plasma miR-92 for CRC screening. Larger
scale validations are underway, as mentioned
in the Discussion section of our original
paper.
In response to comment 4, in our paper
we showed that elevation of plasma miR-92
and miR-17-3p levels is likely to be derived
from CRC. First, miR-92 and miR-17-3p had
been selected for further marker validation
because of their elevated levels in both plasma
and corresponding tumour of patients with
CRC. Secondly, their plasma levels were
signiﬁcantly reduced after surgical removal
of the tumours. Thirdly, elevation of these
miRNAs in plasma due to inﬂammation,
such as inﬂammatory bowel disease, has been
ruled out. Finally, our recent data showed that
plasma levels did not increase in other cancer
types including breast and gastric cancer.
Collectively, miR-92 and miR-17-3p are very
likely to be CRC speciﬁc.
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